Loading...
•
Mar 31, 2025
USANA Q1 2025 Earnings Report
USANA Health Sciences reported its first quarter 2025 financial results, showing growth in net sales and reiterating its full-year outlook.
Key Takeaways
USANA Health Sciences reported net sales of $250 million for Q1 2025, a 10% increase year-over-year, with diluted EPS of $0.49 and adjusted diluted EPS of $0.73. Net earnings were $9.4 million. The company reiterated its full-year 2025 outlook.
Net sales increased by 10% year-over-year to $250 million, and 12% in constant currency.
Net earnings were $9.4 million, a decrease from $16.5 million in the prior year.
Diluted EPS was $0.49, while adjusted diluted EPS was $0.73.
The company reiterated its fiscal year 2025 outlook, anticipating consolidated top line growth of 8% to 17%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
USANA Health Sciences reiterated its fiscal year 2025 outlook, anticipating consolidated net sales between $920 million and $1.0 billion, and adjusted EBITDA between $107 million and $123 million.
Positive Outlook
- Anticipated consolidated top line growth of 8% to 17% for fiscal year 2025.
- Net sales from the direct selling business are projected to be $775 million to $840 million.
- Net sales from Hiya are projected to be $145 million to $160 million, reflecting a year-over-year growth of 29% to 42%.
- Fiscal 2025 is a 53-week year, including one additional week of sales compared to fiscal 2024.
- The company is actively managing inventory levels and sourcing to mitigate potential tariff impacts.
Challenges Ahead
- The impact of potential trade policies and tariffs remains highly uncertain and is not reflected in the financial guidance.
- Potential tariff impact associated with importing raw materials from China into the U.S. and from the U.S. into China.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...